141 related articles for article (PubMed ID: 17372676)
1. Glycoprotein IIb/IIIa blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity.
Razmara M; Hu H; Masquelier M; Li N
Cell Mol Life Sci; 2007 Apr; 64(7-8):999-1008. PubMed ID: 17372676
[TBL] [Abstract][Full Text] [Related]
2. Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition.
Razmara M; Hjemdahl P; Ostenson CG; Li N
J Thromb Haemost; 2008 Dec; 6(12):2186-92. PubMed ID: 18983513
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity.
Hu H; Zhang W; Li N
J Thromb Haemost; 2003 Aug; 1(8):1805-12. PubMed ID: 12911597
[TBL] [Abstract][Full Text] [Related]
4. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction.
Wolfs JL; Comfurius P; Rasmussen JT; Keuren JF; Lindhout T; Zwaal RF; Bevers EM
Cell Mol Life Sci; 2005 Jul; 62(13):1514-25. PubMed ID: 15971000
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Pedicord DL; Thomas BE; Mousa SA; Dicker IB
Thromb Res; 1998 Jun; 90(6):247-58. PubMed ID: 9700855
[TBL] [Abstract][Full Text] [Related]
6. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
7. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects.
Gwozdz AM; Leung R; Wang H; Bang KW; Packham MA; Freedman J; Rand ML
Thromb Haemost; 2010 Jun; 103(6):1218-27. PubMed ID: 20352156
[TBL] [Abstract][Full Text] [Related]
8. Binding of thrombin-activated platelets to a fibrin scaffold through α(IIb)β₃ evokes phosphatidylserine exposure on their cell surface.
Brzoska T; Suzuki Y; Mogami H; Sano H; Urano T
PLoS One; 2013; 8(2):e55466. PubMed ID: 23383331
[TBL] [Abstract][Full Text] [Related]
9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
[TBL] [Abstract][Full Text] [Related]
11. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E inhibition on platelet procoagulant activity: involvement of aminophospholipid translocase activity.
Kim JE; Han M; Hanl KS; Kim HK
Thromb Res; 2011 May; 127(5):435-42. PubMed ID: 21296386
[TBL] [Abstract][Full Text] [Related]
13. Role of thrombin to non-physiological shear stress induced platelet activation and function alternation.
Sun W; Han D; Awad MA; Leibowitz JL; Griffith BP; Wu ZJ
Thromb Res; 2022 Nov; 219():141-149. PubMed ID: 36179652
[TBL] [Abstract][Full Text] [Related]
14. Reassociation and translocation of glycoprotein IIB-IIIA in EDTA-treated human platelets.
Ma Y; Wong K
Platelets; 2007 Sep; 18(6):451-9. PubMed ID: 17763154
[TBL] [Abstract][Full Text] [Related]
15. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
[TBL] [Abstract][Full Text] [Related]
16. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
[TBL] [Abstract][Full Text] [Related]
17. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
18. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
19. Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet-leukocyte interaction and thrombin generation.
Li N; Wallén NH; Savi P; Hérault JP; Herbert JM
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):507-15. PubMed ID: 9819001
[TBL] [Abstract][Full Text] [Related]
20. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
